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ABSTRACT Influenza-infected cells vary widely in their expression of viral genes,
and only occasionally activate innate immunity. Here we develop a new method to
assess how the genetic variation in viral populations contributes to this heterogeneity.
We do this by determining the transcriptome and full-length sequences of all viral
genes in single cells infected with a nominally “pure” stock of influenza virus. Most
cells are infected by virions with defects, some of which increase the frequency of
innate-immune activation. These immunostimulatory defects are diverse, and include
mutations that perturb the function of the viral polymerase protein PB1, large internal
deletions in viral genes, and failure to express the virus’s interferon antagonist NS1.
However, immune activation remains stochastic in cells infected by virions with these
defects, and occasionally is triggered even by virions that express unmutated copies
of all genes. Our work shows that the diverse spectrum of defects in influenza virus
populations contributes to—but does not completely explain—the heterogeneity in
viral gene expression and immune activation in single infected cells.
IMPORTANCE Because influenza virus has a high mutation rate, many cells are in-
fected by mutated virions. But so far, it has been impossible to fully characterize the
sequence of the virion infecting any given cell, since conventional techniques like flow
cytometry and single-cell RNA-seq only detect if a protein or transcript is present—not
its sequence. Here we develop a new approach that uses long-read PacBio sequencing
to determine the sequences of virions infecting single cells. We show that viral genetic
variation explains some but not all of the cell-to-cell variability in viral gene expression
and innate-immune induction. Overall, our study provides the first complete picture of
how viral mutations affect the course of infection in single cells.
KEYWORDS: influenza virus; interferon; PacBio; single-cell RNAseq; 10X Chromium;
NS1; PB1; defective virus; heterogeneity
INTRODUCTION
Infection with an acute virus such as influenza initiates a race between the virus and
immune system. As the virus spreads, some cells detect infection and begin producing
interferon (IFN). This IFN directs expression of anti-viral interferon-stimulated genes
(ISGs) in the infected cell and its neighbors via autocrine and paracrine signaling,
as well as helping launch a broader immune response (1, 2). If innate immunity is
activated sufficiently rapidly, it can reduce viral replication and disease (3, 4, 5, 6, 7)—
although excessive immune responses later in infection can actually be associated with
immunopathology and severe disease (8, 9).
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Unfortunately for the host, influenza initially only rarely triggers IFN production by
infected cells (10, 11). This rareness of IFN induction is just one form of the extreme
cell-to-cell heterogeneity that characterizes infection: cells also vary widely in their
production of viral mRNA, proteins, and progeny virions (12, 13, 14, 15, 16). Because
viral growth and the IFN response both amplify themselves, early variation in the
initiation of these events could have significant downstream consequences for the
race between virus and immune system—especially since natural human infections
are typically founded by just a few virions entering a few cells (17, 18, 19).
It is unclear why only some infected cells trigger innate-immune responses. Two
possible contributors are pure stochasticity and pre-existing variation in cellular state.
For instance, only some cells induce IFN even upon treatment with synthetic innate-
immune ligands (20, 21, 22), and the frequency of IFN induction may depend on a
cell’s pre-existing chromatin state (23). But for influenza, a third possible contribu-
tor also looms large: viral genetic diversity. The virus has evolved mechanisms to
avoid IFN induction, including expressing proteins that interfere with innate-immune
induction (24, 25, 26, 27, 28) and sequestering immunogenic viral RNA (29). However,
because influenza has a high mutation rate (30, 31, 32, 33, 34), individual virions often
have genetic defects that could impair these immune-evasion strategies. Indeed, many
studies have identified mutations that increase IFN induction when engineered into a
viral population (11, 35, 36, 37), and viral stocks that are rich in internal deletions in the
polymerase genes induce more IFN (16, 38, 39, 40, 41, 42).
However, existing techniques are inadequate to determine how viral genetic di-
versity contributes to cell-to-cell heterogeneity during infection. Flow cytometry and
fluorescent reporters only measure protein levels (14, 43, 44), and current single-cell
transcriptomic techniques measure abundance of transcripts and provide only frag-
mentary information on their sequences (12, 13, 16, 45, 46, 47, 48). None of these
techniques reliably reveal if the virion infecting a specific cell has some idiosyncratic
mutation.
Here we develop a new approach to measure both the full transcriptome and
sequences of all viral genes in single influenza-infected cells. To do this, we perform
both standard Illumina-based transcriptomics and full-length PacBio sequencing of
viral genes from single cells. Two-thirds of cells are infected by virions that have a
mutation or defect in gene expression. We identify several types of viral defects that
increase IFN induction, but also show that viral diversity is insufficient to fully explain
cell-to-cell heterogeneity during influenza infection.
RESULTS
A system to identify and enrich rare IFN+ cells. Influenza virus only rarely trig-
gers IFN expression in infected cells (11, 12, 10)—a fact that poses a challenge for the
study IFN induction in single cells. Therefore, we developed a method to identify and
enrich rare IFN+ cells by creating A549 cells that carried IFN reporters consisting of a
type I (IFNB1) or type III (IFNL1) promoter driving expression of a cell-surface protein
(LNGFR∆C (49, 50)) followed by a fluorescent protein (Fig. 1A). Cells that activate the
IFN reporters can be enriched by magnetic-activated cell sorting (MACS) or identified
by flow cytometry. The reporters were efficiently activated by infection with a strain of
Sendai virus (51) that potently induces IFN (Fig. S1A), and activation of the type I and
type III IFN reporters was highly correlated in our cells (Fig. S1B; further validated by
the single-cell transcriptomics below). Therefore, for the rest of this paper, we use “IFN
expression” to refer to combined expression of type I and III IFNs.
We generated a stock of A/WSN/1933 (H1N1) influenza (hereafter referred to as
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FIG 1 Reporter cells to identify and enrich infections that activate IFN expression. (A) The
reporter consists of an IFN promoter that drives expression of a cell-surface protein amenable
to MACS and a fluorescent protein. We created reporters with type I and type III IFN promoters
(File S1). In A549 cells, the reporters were efficiently activated by an IFN-inducing strain of
Sendai virus (Fig. S1A). (B) Frequency of IFN induction upon infection with the influenza virus
stock used in the single-cell studies in this paper, as quantified using the type III IFN reporter
(see Fig. S2 for full flow cytometry data). The plot also shows uninfected cells, and cells infected
with Sendai virus. The limit of detection of 0.05% is indicated with a dashed line, and numbers
show the median of three measurements.
“WSN”) directly from reverse-genetics plasmids (52), and passaged this stock at low
multiplicity of infection (MOI). This process ensures that the viral stock that is relatively
“pure”, with only low levels of the large internal deletions and other defects that arise
in stocks passaged at high MOI (53). As described in the next subsection, our stock
actually consisted of a mix of two viruses: wild-type WSN and a variant of this virus
that carries synonymous viral “barcodes” near the termini of each gene. This viral
stock activated the IFN reporter in ∼0.5% of infected cells (Fig. 1B), a frequency roughly
comparable to that reported in prior studies (11, 12). We also validated that MACS for
the cell-surface protein driven by the IFN reporter enriched the IFN+ cells by >50-fold
(Fig. S3).
Combined transcriptomics and virus-sequencing of single infected cells. We
developed the approach in Fig. 2 to obtain the entire transcriptome and the full se-
quences of all viral genes in single cells. First, we generated the viral stock described
in the previous subsection, which consisted of a mix of wild-type WSN and a “syn-
onymously barcoded” variant that contained two engineered synonymous mutations
near each termini of each gene (File S2). These viral barcodes allow us to identify
co-infections from single-cell transcriptomic data (12), and provide a control for PCR
artifacts during full-length sequencing of viral transcripts (see below). We used this
viral stock to infect A549 IFN reporter cells (Fig. 2A) at a dose that led to detectable viral
transcription in ∼25% of cells (this moderately low MOI reasonably balances our desire
to limit the number of co-infections with the cost of performing transcriptomics on
uninfected cells). From 12 to 13 hours post-infection, we used MACS to enrich cells
that activated the IFN reporter. To ensure the presence of IFN-negative cells, we added
back non-enriched cells to ∼10% of the total. We also added uninfected canine cells to
∼5% of the total as a control for multiplets and to estimate the background amount of
viral mRNA detected in truly uninfected cells.
We processed the cells on a commercially available platform (54) that isolates cells
in droplets and reverse transcribes polyadenylated mRNAs to append a unique cell
barcode to all cDNAs in each droplet, and a unique molecular identifier (UMI) to each
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3'-end sequencing of entire 
transcriptome 
Flu-specific PCR and full-length 
PacBio sequencing
Analyze data to count all transcripts and 
determine full sequences of viruses for
each cell
Cell
A    0     15        0    0     no      none
B    0     13      80   77    yes    wild type
C   12    11      52    0     yes       NS
D    0     18      13    9     yes    NA-A470G
E    21   19      68   57    yes    PB1-A1786C
FIG 2 Approach for combined transcriptomics and viral sequencing of single influenza-infected cells that express IFN. (A) IFN reporter
A549 cells are infected with a mix of wild-type and synonymously barcoded viruses. IFN+ cells are enriched by MACS, and pooled with
non-enriched cells and uninfected canine cells that serve as a control for multiplets and mRNA leakage. (B) The mRNAs from individual
cells are converted to cDNAs tagged with cell-specific barcodes. (C) Cellular transcriptomes are quantified using standard single-cell 3’-end
Illumina sequencing, and (D) viral genes are enriched by influenza-specific PCR and fully sequenced by PacBio (in this schematic, only the cell
labeled by the red barcode is infected and has viral transcripts that are sequenced by PacBio). (E) The result is a matrix giving the expression
of each gene in each cell, as well as the full sequences of the viral genes in infected cells.
process appends cell barcodes to viral as well as cellular mRNAs. Furthermore, because
virtually the entire influenza genome is transcribed, the cell-barcoded cDNA spans
almost all 13,581 nucleotides in the segmented viral genome: the only portions not
covered are one universally conserved nucleotide upstream of the transcription start
site (56) and 17 to 22 highly conserved nucleotides downstream of the polyadenylation
site (55) in each of the eight viral gene segments.
We used a portion of the cell-barcoded cDNA for standard single-cell transcrip-
tomics by Illumina 3’-end sequencing (Fig. 2C). But we also took a portion and enriched
for full-length viral molecules by PCR (Fig. 2D). We performed PacBio sequencing on
these full-length viral cDNAs to generate high-accuracy circular consensus sequences
(CCSs) (57). These CCSs retain the cell barcodes, and with sufficient sequencing depth
we obtain CCSs from multiple unique UMI-tagged cDNAs for each viral gene in each
cell. Because most cells are infected by just one or two virions, we can build a con-
sensus of CCSs for each viral gene in each cell to determine the sequence(s) of these
virions. Combining this information with the 3’-end sequencing determines the entire
transcriptome and the full sequences of the infecting virions in single cells (Fig. 2E).
Transcriptomic analyses of single IFN+ and IFN- influenza-infected cells. We
obtained transcriptomes for 1,614 human (A549) cells, and 50 of the uninfected canine
cells that were spiked into the experiment as a control (Fig. 3A). We also obtained 12
transcriptomes with a mix of human and canine transcripts; from the number of such
mixed cell-type transcriptomes, we estimate (58) that ∼11% of the transcriptomes are
derived from multiple cells. To remove some of these multiplets along with low-quality
droplets, we filtered transcriptomes with unusually high or low numbers of cellular
transcripts as is commonly done in analysis of single-cell RNA-seq data (59). After this
filtering, we retained 1,490 human cells for further analysis (Fig. 3B)
To identify infected cells, we examined the fraction of each transcriptome derived
from virus (Fig. 3C). As expected, only a small fraction (∼0.7%) of transcripts in the
uninfected canine cells were viral; this low-level background is likely from lysed cells
that release ambient viral mRNA. We tested whether each cell contained significantly
more viral transcripts than expected under a Poisson model given this background
fraction, and classified 290 human cells as definitively infected with influenza (Fig. 3C).
We classified the other cells as uninfected, although it is possible that some were
infected with virions that produced very little mRNA. The distribution of the amount
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FIG 3 Single-cell transcriptomics of IFN-enriched influenza-infected cells. (A) Number of cells for which transcriptomes were obtained.
From these numbers, we estimate (58) that ≈11% of the transcriptomes are derived from multiple cells. (B) The number of cellular and viral
mRNAs detected for each cell is plotted as a point. Green lines show the distribution of cellular mRNAs per cell. Cells outside the dashed
magenta lines have unusually low or high amounts of cellular mRNA (likely low-quality emulsions or multiplets), and are excluded from
subsequent analyses. (C) Distribution across cells of the fraction of all mRNA derived from influenza. Cells called as infected are in blue, while
other cells are in green. The inset shows the amount of viral mRNA in the human cells that are called as infected. (D) Number of influenza
genes detected per infected cell, and the amount of viral mRNA in cells expressing each number of viral genes. Fig. S4 shows the frequency
that each viral gene is detected. (E) Relative expression of viral genes, quantified as the fraction of all viral mRNA in each infected cell derived
from each gene. (F) Number of cells infected with wild-type virus, synonymously barcoded virus, or both. From the cells infected with both
viral barcodes, we estimate (58) that 63% of infected cells are co-infected. (G) Fraction of cellular mRNA from IFN across cells, faceted by
whether the cells are infected. Cells to the left of the first dashed magenta line are classified as IFN-, and cells to the right of the second line
as IFN+. A pseudocount is added to the number of IFN transcripts detected in each cell, which is why none of the fractions are zero.
of viral mRNA across infected cells is shown in the inset in Fig. 3C. As in our prior
work (12), the distribution is extremely heterogeneous: many infected cells have only
a few percent of mRNA derived from virus, but viral mRNA comprises over half the
transcriptome of a few cells.
We called the presence or absence of each viral gene in each infected cell, again
using a Poisson model parameterized by background fractions estimated from unin-
fected canine cells. We called presence / absence of genes rather than transcripts, since
the two genes that encode multiple transcripts (M1 / M2 from the M gene, and NS1 /
NS2 from the NS gene) do so via alternative splicing that leaves both isoforms with the
same termini, making them indistinguishable by 3’-end sequencing. Fig. 3D (top panel)
shows that 162 of 290 infected cells express all eight genes (see Fig. S4 for frequencies
for individual genes). This measured frequency of infected cells expressing all eight
genes is slightly higher than in our own prior work using the WSN strain (12), and
slightly to substantially higher than that reported in studies by others using different
viral strains or methodologies (15, 43, 60, 61).
The amount of viral mRNA was lower in cells that failed to express viral genes
(Fig. 3D, bottom panel). However, viral burden remained highly variable even after
conditioning on the number of viral genes: some cells that failed to express one or
even two genes still derived >50% of their mRNA from virus, while other cells that
expressed all genes had only a few percent of their mRNA from virus (Fig. 3D, bottom
panel). Consistent with our prior work (12), despite the wide variation in absolute
expression of viral genes, their relative expression was fairly consistent (Fig. 3E) and
generally matched values from older bulk studies (62).
By examining the synonymous viral barcodes near the 3’ termini of transcripts,
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we determined that 38% of cells were co-infected with wild-type and synonymously
barcoded virions (Fig. 3F; cells called as co-infected if a binomial test rejected null
hypothesis that ≥95% of viral mRNA is from one viral barcode variant). From Fig. 3F, we
estimate (58) that 63% of infected cells are co-infected. Interestingly, this co-infection
rate is higher than expected from the relative numbers of infected and uninfected
cells (Fig. 3C) if infection is Poisson. This discrepancy could arise if the MACS for IFN+
cells also enriches co-infected cells, if infection is not truly Poisson, or if co-infection
complements otherwise transcriptionally defective virions to increase the likelihood
that we identify a cell as infected. The first explanation seems unlikely, as there is no
tendency for co-infected cells to expressmore IFN (Fig. S5). Therefore we favor the latter
two explanations, both of which have been demonstrated for other viruses (63, 64). The
moderately high rate of co-infection may also explain why more cells in our experiment
express all eight viral genes compared to some prior studies, as a co-infecting virion
can complement a missing viral gene.
We next examined expression of IFN and ISGs (Fig. 3G and Fig. S6). Over 20% of
infected cells were IFN+, indicating that the MACS successfully enriched IFN+ cells far
beyond their initial frequency. The expression of type I and type III IFN was highly
correlated in single cells, justifying our decision to collapse both classes under the
single label of “IFN” in the analyses that follow (Fig. S7). Few (∼1.3%) uninfected cells
were IFN+; the few that were present might be because the MACS enriched for rare
cells that activated IFN in response to non-viral ligands (65, 66, 67) or because some
cells that we classified as uninfected were actually infected at low levels. The difference
in the frequency of IFN positivity among infected and uninfected cells in Fig. 3G was
highly significant (P < 10−5, Fisher’s exact test). Many more cells expressed ISGs than
IFN itself (Fig. S6A). The IFN+ cells were a subset of the ISG+ cells: IFN+ cells always
expressed ISGs, but many ISG+ cells did not express IFN (Fig. S6B). These results are
consistent with the established knowledge that IFN is expressed primarily in cells that
directly detect infection, but that ISGs are also expressed via paracrine signaling in
other cells (1, 2).
Finally, we qualitatively examined how expression of viral genes, IFN, and ISGs
relate to the overall structure of the high-dimensional transcriptomic data. Fig. S8
shows unsupervised t-SNE clustering (68) of the cells. Cells expressing high levels of
viral genes, IFN, and ISGs cluster together—and most of the structure in the t-SNE plot
that is not associated with these genes involves uninfected and IFN- cells.
Full genotypes of viruses infecting single IFN+ and IFN- cells. We next used
PacBio sequencing (Fig. 2D, File S3) to determine the full sequences of the viral genes
in single infected cells. We obtained >200,000 high-quality PacBio CCSs that mapped
to an influenza gene and contained a cell barcode and UMI (Fig. S9). The synonymous
viral barcodes at both termini of each gene enabled us to confirm that PCR strand
exchange was rare (Fig. S10), meaning that the vast majority of CCSs correctly link the
sequence of the transcript to cell barcodes and UMIs that identify the cell and molecule
of origin.
After calling the presence / absence of each viral gene in each cell as described
in the previous section, we called mutations if they were found in at least two CCSs
originating from different mRNAs (unique UMIs) and at least 30% of all CCSs for that
gene in that cell. For cells co-infected with both viral barcode variants, we called
mutations separately for each viral variant. This strategy reliably identifies mutations
in virions that initiate infection of cells infected with at most one virion of each viral
barcode variant (∼75% of infected cells), as well as high-abundance mutations in cells
co-infected with multiple virions of the same viral barcode. It will not identify mutations
6































































































































































































































































































































































































































































































































































FIG 4 Viral genotypes and infection outcomes in single cells. Green and orange boxes at the left show the percent of all mRNA in that cell
derived from virus and the percent of all cellular mRNA derived from IFN, respectively. The second box is framed in orange for cells classified
as IFN+ in Fig. 3G. Blue arrows indicate the presence of a viral gene from one (light blue) or both (dark blue) viral barcode variants; a dark blue
arrow therefore means that a cell was co-infected. Circles and boxes on the arrows indicate mutations or indels as described in the legend at
right. The circle areas and box heights are proportional to the fraction of CCSs with that mutation. For dual-barcode infections, mutations /
indels for the wild-type and synonymously barcoded viral variants are shown in the top and bottom half of the arrows, respectively. For
instance, cell 5 was co-infected by a virion with one unmutated and one internally deleted copy of PB1.
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that arise within a cell after the first few rounds of viral genome replication, since such
mutations will not reach 30% frequency in that cell. Therefore, analogous to somatic
variant calling in tumor sequencing (69, 70), there is a limit to our detection threshold:
we cannot identify mutations that occur on just a small fraction of transcripts in a cell.
We could call the sequences of all expressed viral genes in the majority of infected
cells (Fig. S11). We were most effective at calling full viral genotypes in cells that
expressed high amounts of viral mRNA and were infected by only one viral barcode
variant (Fig. S11). But we also called full genotypes for many cells that had low viral
burden or were co-infected by both viral barcode variants.
The 150 cells for which we called the full viral genotypes are shown in Fig. 4 (see
also File S4). Visual inspection of this figure reveals a wealth of information. For
instance, the cell with the highest viral burden (cell 1 in Fig. 4, which has 65% of its
mRNA from virus) was infected by a virion that expressed unmutated copies all eight
genes and did not induce detectable IFN. But 12 of the other 13 cells with at least
50% of their mRNA from virus were infected by virions that had a mutation or failed
to express a gene, and five of these cells produced IFN. As expected, all cells infected
by virions that failed to express a component of the viral polymerase complex (PB2,
PB1, PA, or NP) expressed low amounts of viral mRNA since they are limited to primary
transcription using incoming proteins (e.g., cell 132 and cell 143). The two cells that
expressed the most IFN (cell 13 and cell 123) lacked the viral NS gene that encodes the
virus’s primary IFN antagonist (24, 25). Many other IFN+ cells had different defects such
as large internal deletions (e.g., cell 5 and cell 89) or amino-acid mutations (e.g., cell 9,
cell 28, and many others).
However, Fig. 4 also reveals stochasticity that is independent of viral genotype.
This stochasticity sometimes acts to the detriment of the virus, and sometimes to
the detriment of the cell. As an example of the former case, expressing unmutated
copies of all eight genes did not guarantee high viral gene expression and successful
innate-immune evasion: for instance, the unmutated virion that infected cell 139 only
managed to express viral mRNA to 6% of the total transcriptome, and the unmutated
virion that infected cell 105 still induced IFN. But in other cases, the stochasticity allows
a defective virus to still escape immune recognition. For instance, there are a number
of cells (e.g., cell 62 and cell 78) that do not activate IFN despite being infected by virions
that fail to express NS.
Viral defects associated with viral gene expression and IFN induction in sin-
gle cells. To systematically assess viral features associated with infection outcome, we
divided the 150 cells in Fig. 4 into those that expressed unmutated copies of all eight
genes (disregarding synonymous mutations) and those that did not. Fig. 5A shows that
the 49 cells infected by full unmutated virions had a significantly tighter distribution of
the amount of viral mRNA per cell than the other 101 cells as quantified by the Gini
index (71) (see also File S5). Therefore, viral defects are a major contributor to the
heterogeneity in viral transcriptional burden.
Some viral defects also contribute to IFN induction. Specifically, cells infected by
incomplete or mutated virions expressed IFN more frequently than cells infected by
virions that expressed unmutated copies of all genes (Fig. 5B), although this difference
was not statistically significant (P = 0.12, Fisher’s exact test). However, the association
was significant for certain classes of viral defects: absence of NS and amino-acid
mutations in PB1 were significantly enriched in IFN+ cells, and amino-acid mutations in
NS and deletions in HA were weakly enriched (Fig. 5C). The only trend that remained
significant at a false discovery rate (FDR) of 10% was absence of NS. This lack of
statistical significance after FDR correction could be due to the relatively modest
8
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FIG 5 Viral features associated with heterogeneity in infection outcome among cells for which we determined viral genotypes. (A) Percent
of all mRNA derived from virus, faceted by whether cells express unmutated copies of all eight genes. Cells infected by fully unmutated
virions exhibit less heterogeneity in viral burden as quantified by the Gini index (95% confidence intervals are indicated). (B) IFN expression
among cells expressing unmutated copies of all genes, and among cells with mutations or missing genes. (C) Specific viral defects associated
with IFN induction. The top panel show the percent of IFN- and IFN+ cells that fail to express each viral gene. The middle and bottom panels
show the percent of IFN- and IFN+ cells that have a deletion or amino-acid substitution in each gene, conditioned on the cell expressing that
gene. Numbers give P-values (Fisher’s exact test) for rejecting the null hypothesis that percents are equal among IFN- and IFN+ cells. (D)
There is no association between IFN induction and the amount of viral mRNA in cells that express NS, but viral burden is associated with IFN
induction among cells that lack NS. Throughout this figure, we only consider substitutions that are non-synonymous.
number of fully sequenced infected cells (just 150). The validation experiments in the
next section show that many of the viral mutations in IFN+ cells do in fact increase the
rate of IFN induction.
One other interesting trend emerges from the single-cell data. There is no dif-
ference in the amount of viral mRNA between IFN+ and IFN- cells that express NS
(Fig. 5D). But among cells that lack NS, cells with more viral mRNA are significantly more
likely to be IFN+ (Fig. 5D); this finding is elaborated on in the validation experiments
below. Overall, the lack of reduced viral gene expression in IFN+ cells suggests that
autocrine IFN signaling typically occurs too late to suppress viral transcription, and
the well-known inhibitory effect of IFN against influenza depends mainly on paracrine
signaling.
Validation that viral defects in single IFN+ cells often increase IFN induction.
To test if the viral defects identified in single IFN+ cells cause increased IFN expression,
we used reverse genetics to generate bulk stocks of viruses with some of these defects.
The viral defect most strongly associated with IFN induction was failure to express
the NS gene (Fig. 4, Fig. 5C). Although it is sometimes possible to use complementing
cells to generate influenza viruses lacking a specific gene (72, 73), we were unable to
generate viruses that lacked NS. The NS gene encodes two proteins (NS1 and NS2), the
first of which is influenza’s primary innate-immune antagonist (24, 25). We therefore
mimicked the absence of NS by creating a mutant virus (which we term “NS1stop”) that
had multiple stop codons early in the NS1 coding sequence.
The single-cell data also showed that amino-acid substitutions in proteins encoded
by the PB1 and NS genes were enriched in IFN+ cells (Fig. 4, Fig. 5C), so we created
mutant viruses with some of these substitutions: PB1-D27N, PB1-G206S, PB1-K279R,
PB1-T677A, NS1-A122V, and NS2-E47G.














































































































FIG 6 Validation that IFN induction is increased by some of the mutations identified in the
single-cell virus sequencing of IFN+ cells. (A) Percent of infected cells that become IFN+ after
infection with a bulk stock of the indicated viral mutant, as determined using a reporter cell line.
The numbers indicate the median of four measurements for each viral mutant. The limit of
detection of 0.05% is indicated with a dashed green line, and the median value for the wild type
viral stock is indicated with a dashed blue line. Points are colored orange if the mutant virus
stock induces IFN more frequently than the wild-type viral stock (one-sided t-test, P < 0.01), and
blue otherwise. (B) Similar to the first panel, but validates increased IFN induction for a large
internal deletion in the PB1 gene, and normalizes infecting virion dose rather than calling IFN+
percentage only among infected cells. See Fig. S12 and Fig. S13 for details. The experiments
in the two panels were performed on different days, and so numerical values can be reliably
compared within panels but not between panels.
merase genes can induce higher levels of IFN (16, 38, 39, 40, 41, 42). Although such
deletions are not significantly enriched among IFN+ cells in our single-cell data (Fig. 5C),
there is a co-infected IFN+ cell where one viral variant has a deletion in PB1 spanning
nucleotides 385 to 2163 (cell 5 in Fig. 4). We therefore created a virus carrying this
deletion, and propagated it in cells constitutively expressing PB1 protein.
We tested the rate of IFN induction by each viral stock using the reporter cells.
Fig. 6 shows that five of the eight mutant viral stocks induced IFN more frequently than
a wild-type viral stock. The strongest IFN induction was by the NS1stop virus, but the
PB1 internal deletion and three of the point-mutant viruses (PB1-D27N, PB1-T677A,
and NS1-A122V) also induced IFN significantly more frequently than wild type. The
other three point mutants (PB1-G206S, PB1-K279R, and NS2-E47G) did not increase
IFN induction—an unsurprising finding, since we expect some mutations without an
IFN-enhancing effect to be found in IFN+ cells by chance. Overall, the results in Fig. 6
validate that the viral defects in single IFN+ cells often cause increased IFN production.
However, IFN induction remains stochastic even for the most potently IFN-inducing
viral mutants. Fig. 6 shows flow cytometry data (see also Fig. S12), which is itself a
single-cell measurement, albeit one that does not report the viral genotype. As can
be seen from these data, none of the mutant viral stocks induce IFN in more than
20% of infected cells. Of course, these mutant virus stocks are themselves genetically
heterogeneous, as many virions will have additional defects similar to that revealed by
our single-cell sequencing of the “wild-type” viral stock. But our single-cell data show
that IFN induction is stochastic even for infections that share the same defect, such as
absence of NS (e.g., compare cell 62 and cell 69 in Fig. 4). Therefore, the experiments in
this section not only validate some specific viral defects that increase IFN induction,
but also show that induction remains stochastic even with these defects.
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FIG 7 Infected cells that express higher levels of HA protein are much more likely to induce
IFN expression only if they are infected by virus with defects in NS1. The y-axis shows the
ratio of the percent of IFN+ cells in the highest HA-expression quartile relative to the lowest
HA-expression quartile. Points indicate replicates, and lines indicate the mean. This figure
is based on joint analysis of the IFN reporter and HA staining for all infected cells in the flow
cytometry data in Fig. S12; see Fig. S14 for more details.
The IFN-inducing viral defects act by diverse mechanisms. Some of the viral
defects in IFN+ cells are easy to reconcile with existing knowledge: for instance, NS1
is the virus’s primary IFN antagonist (24, 25), and internal deletions are prevalent
in immunostimulatory viral stocks (16, 38, 39, 40, 41, 42). Other defects are more
surprising: for instance, it is not obvious why amino-acid mutations in PB1 increase IFN
induction. We therefore designed experiments to interrogate some of these defects in
more detail.
We first focused on one of the strongest trends from the single cell data: increased
viral gene expression is associated with increased IFN induction when the infecting
virion fails to express NS, but not otherwise (Fig. 5D). To confirm this observation,
we performed a flow cytometry analysis of the reporter cells infected by different
immunostimulatory viral mutants to examine the association between expression of a
viral gene product (HA protein) and IFN induction. Consistent with the single-cell data,
cells that expressed more HA were much more likely to turn IFN+ when infected with
the NS1stop or NS1-A122V mutants, but not when infected with any of the other viral
variants (Fig. 7). This fact suggests that when there are high levels of viral transcription,
NS1 becomes more important as a buffer against detection of viral products.
We hypothesized that the immunostimulatory mutations to PB1 might cause the
viral polymerase to produce aberrant products, in line with recent work showing that
mutations to PB2 can lead to the generation of aberrant RNAs that trigger RIG-I (35, 36).
To investigate if the PB1 mutations might perturb polymerase activity, we examined
their location in a structural model of the polymerase complex (Fig. 8A). The IFN-
enhancing PB1 mutation T677A occurs at the tip of a helix that interacts with the 3’
terminus of the RNA template as it enters the channel above the active site, whereas
the IFN-enhancing D27N mutation is deeper in the polymerase close to the binding
pocket of the 5’ terminus of the template. Therefore, both mutations could plausibly
alter the polymerase’s interactions with the RNA template.
To test if the PB1 mutations affect activity, we transfected 293T cells with plasmids
that express wild-type or mutant PB1 protein along with the other proteins in the
polymerase complex (PB2, PA, and NP) and full-length viral RNA (vRNA) for the NA
segment. Both polymerase mutations increased IFN expression in this assay (Fig. 8B),
indicating that they have an immunostimulatory effect in the context of an active
viral polymerase even when other viral components are absent. We next directly




































































































































































































FIG 8 IFN-inducing mutations D27N and T677A in the PB1 protein affect polymerase activity.
(A) Model of bat influenza A virus polymerase (PDB 4WSB) (74) superposed with the influenza B
virus polymerase (PDB 5MSG) (75). The locations of PB1 D27 and T677 (both red) relative to the
5’ (blue) and 3’ (orange) termini of the RNA template and the PB1 active site (grey; PB1 act) are
indicated. The PA endonuclease (green; PA endo) and PB2 cap binding domain (pink; PB2 cap)
are also indicated. Part of the fingers subdomain of PB1 is hidden to reveal the template in
the entry channel. (B) IFN-beta promoter activity measured using a dual luciferase reporter
assay in 293T cells transfected with plasmids expressing the indicated PB1 protein, the other
polymerase complex proteins (PB2, PA, and NP), and a full-length NA vRNA template. PB1a is a
catalytically inactive PB1 active site control. In this panel and the next two panels, points show
three biological replicates; “n.d.” indicates not detectable, and orange indicates a variant was
significantly different than wild type by a two-sided t-test. (C) Polymerase activity on full-length
vRNA template in 293T cells transfected as in panel (B). Steady-state RNA levels were measured
by primer extension, denaturing PAGE, and phosphorimaging. PB1a was used as negative
control and background correction. The 5S rRNA signal was used as loading control. Other
panels show Western blot analysis of PB1, NP and GAPDH protein expression, and the graph
at the bottom shows quantification by phosphoroimaging. (D) Polymerase activity on a short
246-nucleotide vRNA template. The top panel shows the steady state levels of vRNA template
as determined by primer extension and denaturing PAGE. The other two panels show the PB1
and tubulin expression levels analyzed by Western blot, and the graph shows quantification.
RNA and quantifying replication (vRNA) and transcription (mRNA) products by primer
extension. Both immunostimulatory PB1mutations had activities that were significantly
different from wild type, despite being expressed at wild-type protein levels (Fig. 8B).
Specifically, T677A had higher levels of both activities, whereas D27N had reduced
levels of both—although D27N still retained activity far in excess of a control active-site
mutant (Fig. 8C). We speculated that the mutations might alter polymerase processivity,
leading to accumulation of aberrant RNA products that activate the innate immune
system (35, 38, 39, 40, 41, 42). We therefore repeated the activity assays using a
short 246-nucleotide template (35) in place of the full-length NA vRNA (Fig. 8D). On
this shorter template, the activity of the D27N mutant was now similar to wild type,
while the activity of the T677A mutant remained higher than wildtype (although not
significantly so in three biological repeats). Therefore, the two immunostimulatory PB1
mutations have distinct effects on the polymerase: D27N reduces processivity thereby
favoring shorter RNA products, whereas T677A increases overall activity which could
also lead to accumulation of aberrant RNA products.
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Overall, the results in this section show that the diverse range immunostimulatory
viral defects identified in single cells act by diverse processes, showing that viral varia-
tion influences not only the rate of IFN induction but also the factors that contribute to
this induction.
DISCUSSION
We have determined the full sequences of all viral genes in single influenza-infected
cells. Methodologically, our major advance is to measure the genotypes of viruses in
addition to the abundance of viral components (i.e., transcripts, proteins, or progeny
virions) as has been done by prior single-cell studies (12, 13, 15, 16, 14, 43, 45, 46,
47, 48, 76, 77, 78). Our method builds on the observation that fragmentary viral
genetic information can be obtained by more standard single-cell transcriptomic tech-
niques (16, 46, 47). To make this information complete, we have coupled single-cell
transcriptomics with long-read PacBio sequencing of viral genes, a strategy analogous
to that used by (79) to obtain full-length isoforms of some cellular genes in single cells.
This viral genetic information helps explain cell-to-cell variation in viral gene ex-
pression and innate-immune induction. Despite the fact that we used a low-passage
viral stock generated from plasmids, most infected cells do not express unmutated
copies of all viral genes. Although our study is certainly not the first to note that
influenza has a high mutation rate (30, 31, 32, 33, 34) and sometimes fails to express
genes (12, 15, 43, 60, 61), it is the first to directly observe the full spectrum of these
defects across single cells. Visual inspection of Fig. 4 shows how any experiment that
does not sequence viral genes in single cells is averaging across a diverse spectrum of
viral defects.
We identified four types of defects that we validated to increase IFN induction.
Two types of defects—absence of the NS gene and amino-acid mutations to the
NS1 protein—presumably impair NS1’s well-known ability to antagonize innate im-
munity (24, 25). But although the general role of NS in innate-immune antagonism
has long been appreciated, our work represents the first direct demonstration that
stochastic absence and mutations to this gene are a major contributor to IFN induction
in single cells. A third type of defect, amino-acid mutations in PB1, was more surpris-
ing since this protein has not been described as a major player in innate-immune
detection. We characterized two IFN-inducing PB1 mutations, and showed that one
impaired polymerase processivity whereas the other increased overall activity. We
speculate that these alterations increase production of aberrant immunostimulatory
RNA products (35). Finally, we found an internal deletion in PB1 that enhances IFN
induction, consistent with prior work showing such deletions are immunostimula-
tory (38, 39, 40, 41, 42). In fact, given the extensive prior work on deletions, we were
surprised not to identify more of them in our IFN+ cells. There may be several reasons:
we used pure viral stocks (53) at modest MOI; our experiments preferentially captured
cells with higher viral transcriptional load; and most prior studies have used techniques
that can detect large deletions but not subtle point mutations. Additionally, the relative
importance of different defects likely varies across infection conditions, viral strains,
and cell types: it is an open question which defects are most relevant for immune
detection during actual human infections.
However, the greatest value of our work is not as a screen for IFN-inducing defects,
but rather as a relatively unbiased survey of the breadth of viral variation in individual
infected cells. This survey shows that no single type of viral defect determines whether
a cell induces IFN: even the most immunostimulatory defect (absence of NS) occurs in
only about a quarter of IFN+ cells. Therefore, innate-immune detection of influenza is
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a multi-faceted process that cannot be ascribed a single dominant viral genetic cause.
Our results further show that viral genetic defects do not fully explain the hetero-
geneity among influenza-infected cells. There is substantial breadth in viral transcrip-
tional burden and occasional IFN induction even among cells infected with unmutated
virions. Additionally, no viral defect induces IFN deterministically: every type of im-
munostimulatory defect that we characterize is also observed in IFN- cells in our
single-cell dataset. Therefore, stochasticity or pre-existing cellular states also play a ma-
jor role in affecting innate-immune induction—a finding that concords with the fact that
IFN induction is heterogeneous even among cells treated with synthetic innate-immune
ligands (20, 21, 22, 23), as well as for other viruses (48).
Perhaps the most intriguing question is how the heterogeneity that we have
described ultimately affects the macroscopic outcome of infection. Natural human
influenza infections are established by just a handful of virions (17, 18, 19) that then
undergo exponential growth, and early IFN responses are amplified by paracrine
signaling (1, 2). It is therefore plausible that early heterogeneity in innate-immune
induction could affect the entire course of infection. Extending our approaches to
more complex systems could shed further light on how viral genetic variation and
stochasticity interact to shape the race between virus and immune system.
MATERIALS AND METHODS
IFN reporter cell lines. We created IFN reporter variants of the A549 human lung epithelial
cell line (Fig. 1A). The parental A549 cell line used to create these reporters was obtained
from ATCC (CCL-185), and was tested as negative for mycoplasma contamination by the Fred
Hutch Genomics Core and authenticated using the ATCC STR profiling service. The cells were
maintained in D10 media (DMEM supplemented with 10% heat-inactivated fetal bovine serum,
2 mM L-glutamine, 100 U of penicillin / ml, and 100 µg of streptomycin / ml) at 37◦C and 5%
carbon dioxide.
To create the type I interferon reporters, a 1kb promoter region upstream of the human
IFNB1 gene were cloned into the pHAGE2 lentiviral vector (80), with a NotI site immediately
downstream of the promoter serving as an artificial Kozak sequence. Downstream of this
NotI site, each of the following reporter constructs was cloned: mCherry, mNeonGreen, and
low-affinity nerve growth factor lacking the C-terminal signaling domain (LNGFR∆C) (49, 50)
linked to mNeonGreen by a P2A linker (81). The sequence of the last of these constructs is
provided in File S1.
To create the type III interferon reporters, a 1.2kb region upstream of the human IL29
(IFNL1) gene was cloned into the pHAGE2 vector, with the native Kozak sequence retained at
the 3’ end. Downstream of this promoter we cloned LNGFR∆C linked to ZsGreen via a P2A
linker. The sequence of this construct is provided in File S1.
We used these constructs to generate lentiviral vectors and transduce of A549 cells in the
presence of 5 µg polybrene. We then sorted single transduced cells and expanded them. A
portion of the expanded cells were tested for reporter activity by transfecting poly(I:C) (a potent
agonist of the RIG-I pathway), and we retained clones with strong activation. Importantly, the
cells that we retained for further use were not the same portion that were tested by poly(I:C)
treatment, but rather a separate split of the same population—this avoids any selection on the
cells from transient activation of IFN. For the dual type I / type III reporter used in Fig. S1B, a
single-cell clone of the type III reporter cell line was transduced with the type I reporter bearing
the mCherry fluorescent marker, and then isolated and propagated as a single cell clone for
the other cell lines. All reporter lines tested negative for mycoplasma contamination by the
Fred Hutch Genomics Core.
Fig. S1A shows validation of the reporter cell lines using infection with saturating amounts
of the Cantell strain of Sendai virus (obtained from Charles River Laboratories). For detection
of the cell-surface bound LNGFR∆C, cells were stained with PE-conjugated anti-LNGFR (CD271)
antibody from Miltenyi Biotec.
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Viruses for single-cell experiments. We performed the single-cell experiments using the
A/WSN/1933 (H1N1) strain of influenza virus. We used both the wild-type virus and a variant
of the virus where synonymous mutations were added within a few 100 nucleotides of each
termini of each gene segment. We have used a similar synonymous viral barcoding strategy in
our prior single-cell work (12) as it allows us to detect about half of co-infected cells based on
the expression of both viral barcode variants. In the current work, we extended this approach
by placing synonymous barcodes near both termini of the gene segments in order to quantify
strand exchange during PacBio sequencing (Fig. S10). The sequences of all gene segments from
the wild-type and synonymously barcoded viral strains are in File S2. These genes were cloned
into the pHW2000 (52) reverse-genetics plasmid.
Both viral strains were generated by reverse genetics using the pHW18* series of bi-
directional plasmids (52). We controlled the durations and MOI during viral passaging since
these factors can greatly affect the accumulation of defective viral particles (53). The viruses
were generated by reverse genetics in co-cultures of 293T and MDCK-SIAT1 cells in influenza
growth media (Opti-MEM supplemented with 0.01% heat-inactivated FBS, 0.3% BSA, 100 U
of penicillin/ml, 100 µg of streptomycin/ml, and 100 µg of calcium chloride/ml) and then
propagated in MDCK-SIAT1 cells in influenza growth media using the same basic procedures
detailed in (12). Specifically, after generation by reverse genetics, the wild-type variant was
expanded at an MOI of 0.001 for 72 hours twice in MDCK-SIAT1 cells, and the synonymously
barcoded variant was expanded once at an MOI of 0.01 for 60 hours. The MOIs for this
passaging are based on titers determined using TCID50 assays via the formula of Reed and
Muench (82) as implemented at https://github.com/jbloomlab/reedmuenchcalculator. After
being passaged independently, the two viral stocks were combined at equivalent numbers of
infectious units to make the stock used in the single-cell experiments.
Flow cytometry analyses for HA expression. For the single-cell experiments (which only
examine the transcriptional results of a single cycle of infection), we were most interested in
the titer of viral particles that are transcriptionally active for a single round of infection of A549
cells. We estimated titers of transcriptionally active virions by staining for HA expression in
virus-infected A549 cells. Specifically, we infected A549 cells (or one of the A549 reporter cell
line variants as indicated) in influenza growth medium, and at 13 to 14 hours post-infection,
we trypsinized cells, re-suspended in phosphate-buffered saline (PBS) supplemented with 2%
heat-inactivated fetal bovine serum (FBS), and stained with 10 µg/ml of H17-L19, a mouse
monoclonal antibody previously shown to bind to the HA from the A/WSN/1933 strain of
virus (83). After washing in PBS supplemented with 2% FBS, the cells were stained with a goat
anti-mouse IgG antibody conjugated to APC, washed, fixed in 1% formaldehyde in PBS, washed
again, and then analyzed by flow cytometry to determine the fraction expressing detectable HA
protein.
Single-cell transcriptomics of IFN-enriched infected cells using 10X Chromium. The
single-cell transcriptomics and virus sequencing was performed using the A549 cells with the
IFNB1 LNGFR∆C-P2A-mNeonGreen reporter. A schematic of the experiment is shown in Fig. 2.
The wild-type and synonymously barcoded viruses were mixed with the goal of adding
equal numbers of transcriptionally active HA-expressing virions of each virus strain. The cells
were then infected with this mixture at a dose designed to infect about half the cells (Fig. 3C
suggests that the actual rate of detectable infection was slightly lower). Infections were allowed
to proceed for 12 hours. The cells were then trypsinized, the trypsin was quenched with D10
media, and cells were resuspended in de-gassed PBS supplemented with 0.5% bovine serum
albumin and 5 mM EDTA. To enrich IFN+ cells, the cells were then incubated with anti-LNGFR
MACSelect Microbeads (Miltenyi Biotec) and twice passed over anMSmagnetic column (Miltenyi
Biotec), retaining the bound (and presumably IFN-enriched) population each time. This MACS
sorting is expected to give approximately the enrichment for IFN+ cells shown in Fig. S3. The
original, unsorted, population was then added back in to ∼10% of the final cell fraction in
order to ensure the presence of interferon negative cells. At this point, uninfected canine
(MDCK-SIAT1) cells were also added to ∼5% of the final cell fraction to enable quantification
of the cell multiplet rate (Fig. 3A) and background viral mRNA in uninfected cells (Fig. 3C). We
began this entire process of cell collection and enrichment at 12 hours post-infection, but
the process (which was performed at room temperature) took about an hour, and thus we
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consider the cells to have been analyzed at 13 hours post-infection. The final cell suspension
was counted using a disposable hemocytometer and loaded on the 10x Genomics Chromium
instrument (54), targeting capture of ∼1,500 cells.
This sample was then processed to create libraries for Illumina 3’-end sequencing according
to the 10X Genomics protocol using the Chromium Single Cell 3’ Library and Gel Bead Kit v2
with one important modification: rather than process all full-length cDNA through enzymatic
fragmentation, several nanograms were retained for targeted full-length viral cDNA sequencing
as described below. The single-cell transcriptomics library was sequenced on an Illumina HiSeq
2500, and the data analyzed as described below.
Enrichment and preparation of viral cDNA for PacBio sequencing. We amplified virus-
derived molecules from cDNA retained from the 10X Genomics protocol for PacBio sequencing
of the full-length cDNA. These cDNA have at their 3’ end the cell barcode and UMI plus the
adaptor sequence that is added during the 10X protocol (see Fig. 2 for simple schematic, and
File S7 for more details). We only wanted to PacBio sequence cDNA molecules derived from
virus. We therefore needed to enrich for the viral molecules while retaining the 10X adaptor /
UMI / cell barcode at the 3’ end.
We first performed a multiplex PCR reaction on 1 ng of the full-length 10X cDNA using a 3’
primer complementary to the common 10X adaptor, and a multiplex mix of eight 5’ primers,
one specific for the mRNAs from each of the eight viral gene segments (File S3). A major
concern during these PCRs is strand exchange (see Fig. S10) which would scramble the cell
barcodes and mutations on viral cDNAs. To reduce strand-exchange and obtain more even
PCR amplification across segments, we performed emulsion PCRs using the Micellula DNA
Emulsion Kit (Roboklon), which physically separates disparate template molecules, preventing
strand exchange and allowing each molecule to be amplified to exhaustion of its droplet’s
reagents (84). We performed the PCRs using Kapa HiFi Hotstart ReadyMix, supplementing the
reactions with additional BSA to a final concentration of 0.1 mg/ml and using a volume of 100µl.
Both the common 3’ primer and the multiplex mix of eight 5’ primers were added to a final
concentration of 0.5µM. We performed 30 cycles of PCR, using an extension time of 2 minutes
15 seconds at 67◦C, and a melting temperature of 95◦C. This melting temperature is lower
than the standard 98◦C melting step suggested by the manufacturer for Kapa HiFi because we
wanted to avoid collapse of emulsion integrity at high temperature.
The product of this multiplex PCR was subjected to eight additional individual emulsion
PCR reactions, each using only a single segment-specific 5’ primer as well as the common 3’
primer, using 1 ng of material in each reaction. The material from these eight segment-specific
PCRs was then pooled with the goal of obtaining a equimolar ratio of segments, and sequenced
on one SMRT Cell in a PacBio RS II and one SMRT Cell of a PacBio Sequel. Detailed results from
the analysis of these first two sequencing runs is shown in File S7. These results showed that
although the PCRs substantially enriched for influenza molecules, the relative coverage of the
different viral genes was still uneven, with the longer genes under-sampled.
To improve coverage of the polymerase genes, we produced two new sequencing pools:
one consisting of the five shortest viral segments (HA, NP, NA, M, and NS) from the afore-
mentioned segment-specific emulsion PCRs, and the other consisting of the three longer
polymerase segments (PB2, PB1, and PA). The former was sequenced on one cell of a single
SMRT Cell of a PacBio Sequel, and the latter on two additional SMRT Cells of a PacBio Sequel.
As is shown File S7, the coverage remained relatively low for the polymerase genes—and
most of the reads we did obtain were dominated by shorter internally deleted variants of the
polymerase genes (53) which are preferentially amplified during PCR.
To obtain more reads for longer full-length polymerase variants, we therefore subjected 10
ng of our amplified material for each polymerase segment to a bead selection using SPRIselect
beads at a volume ratio of 0.4. This selection removes most low-molecular weight DNA species
including internally-deleted defective segments. Material from this selection was amplified
using 16 (PB1) or 14 (PB2 and PA) cycles of a non-emulsion PCR using the standard conditions
recommended by the Kapa HiFi Hotstart ReadyMix (extension at 67◦C for 2 minutes 15 seconds,
and melting at 98◦C ). The use of relatively few PCR cycles was designed to prevent the
occurrence of the artifacts (including strand exchange) that occur in non-emulsion PCRs. We
pooled the products of these reactions from this size-selection and sequenced on a SMRT Cell
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of a PacBio Sequel. As is shown in File S7, this sequencing yielded more full-length polymerase
variants, but they were still undersampled compared to other viral genes.
To further to improve recovery of full-length PB1, PB2, and PA, we use an approach that
allowed us to perform a specific PCR for full-length polymerase variants. We circularized the
template molecules, and then used two segment-specific primers that annealed in apposition
near the center of each polymerase gene to linearize these circular molecules. Only molecules
that contain the middle of the polymerase genes (which are typically full-length) are linearized
by this process. In the downstream computational analysis, we can then determine the full
sequence of the gene as well as the cell barcode of the initial molecule fromwhich the linearized
molecule is derived. Specifically, we first used 2.5 ng of our already-amplified segment-specific
material in a 10-cycle PCR to append circularization adapters (see File S3 for sequences), and
cleaned the resultant mixture using SPRIselect beads at a volume ratio of 0.4. We then used 10
ng of this amplified material in a 20µl NEBuilder reaction using an extended reaction time of 50
minutes in order to circularize the molecules. We next incubated these reactions for 1 hour
at 37◦C with exonuclease V and additional ATP to a final increase in concentration of 1 mM to
digest all non-circularized molecules. The circularized and digested material was then cleaned
using SPRIselect beads at a volume ratio of 0.4. This material was then used as template for
three non-emulsion PCRs specific to PB2, PB1, or PA, using two segment-specific primers that
align to the central portion of each gene but in apposition to each another (see File S3 for
sequences). These linearization reactions used 20 (PB2) or 26 (PB1 and PA) PCR cycles, and the
resulting products were cleaned using SPRIselect beads at a volume ratio of 1.0. This material
was pooled to produce an equimolar mixture of full-length PB1, PA, and PB2 and sequenced
in an additional SMRT Cell of PacBio Sequel. As is shown in File S7, this process yielded many
full-length polymerase variants.
The computational analyses of the full-length viral gene sequences described below com-
bined the data from all these reactions. The number of sequences obtained for each gene after
pooling the data from all reactions is shown in Fig. S9, which also indicates that the net rate
of strand exchange is very low (see Fig. S10 for an illustration of how this is determined). A
detailed breakdown of the coverage of each gene and PacBio run is in File S7. Importantly, the
PCR biases mean that the coverage of molecules by the PacBio sequencing is not proportional
to their abundance in the starting mRNA. However, as described in the computational anal-
ysis section below, the final analyses use the cell barcodes and UMIs in conjunction with the
standard 10X Illumina sequencing to ensure that none of the conclusions are affected by the
disproportionate amplification of some molecules during the PacBio library preparation (for
instance, duplicate UMIs are removed from the PacBio data, and all conclusions about gene
abundance or absence are based on the Illumina data).
qPCR for viral genes and IFN. We performed qPCR on reverse-transcribed mRNA for
influenza HA (to quantify viral transcription), IFNB1 (to quantify IFN induction), and L32 (a
cellular housekeeping gene for normalization). For the qPCR, we used the SYBR Green
PCR Master Mix (Thermo Fisher) according to the manufacturer’s protocol using oligo-dT
primers. The qPCR primers were: HA primer 1, 5’-GGCCCAACCACACATTCAAC-3’; HA primer
2, 5’-GCTCATCACTGCTAGACGGG-3’; IFNB1 primer 1, 5’-AAACTCATGAGCAGTCTGCA-3’; IFNB1
primer 2, 5’-AGGAGATCTTCAGTTTCGGAGG-3’; L32 primer 1, 5’-AGCTCCCAAAAATAGACGCAC-3’;
L32 primer 2, 5’-TTCATAGCAGTAGGCACAAAGG-3’.
For the qPCR in Fig. S13, A549 cells were seeded at a density of 104 cells/well in a 96-
well plate in D10 media 24 hours prior to infection, with four independent wells seeded per
experimental treatment. Immediately prior to infection D10 media was removed and replaced
with influenza growth media and infected with the indicated influenza strains at a MOI of
0.4 based on TCID50 in MDCK-SIAT1 cells. For the cells with cycloheximide added to block
protein expression (and hence secondary transcription), cycloheximide was added to a final
concentration of 50 µg/ml (a concentration sufficient to block secondary transcription (85))
at the time of infection. After 8 hours, mRNA was harvested using the CellAmp Direct RNA
Prep Kit for RT-PCR, reverse-transcribed using an oligo-dT primer, and qPCR was performed as
described above.
Viruses and experiments for validation experiments. In Fig. 6, we tested the IFN in-
ducing capacity of a variety of viral mutants identified in the single-cell experiments. For
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point-mutant viruses, we created variants for all amino-acid substitutions found in PB1 and
NS among IFN+ cells that did not also lack NS. One of these mutants (amino-acid substitution
S704P in PB1) did not reach sufficient titers in a single attempt to generate it by reverse ge-
netics, and so was dropped from the experiment (note that we did not attempt replicates of
the reverse genetics for this mutant, and so are not confident in drawing strong conclusions
about its actual attenuation). This left six point-mutant viruses: four with point mutations in
PB1, and two with point mutations in NS. We also created a mutant virus that contained the
internal deletion in PB1 found in an IFN+ cell. In addition, we created a virus with an inactivated
NS1 to mimic the infections that failed to express NS (we were unable to use complementing
cells to generate a viral stock that completely lacked the NS segment). This NS1stop virus
contained six nucleotide changes resulting in the addition of five in-frame stop codons in NS1
starting 10 nucleotides downstream of the 5’ splice donor site, thereby disrupting NS1 while
leaving NS2 (NEP) intact. All of these mutants were cloned into the pHW2000 bi-directional
reverse-genetics plasmid (52) in order to enable generation of viruses encoding the mutant
genes. File S6 provides the full sequences for all of these plasmids.
We generated the wild-type and point-mutant viruses for the validation experiments in
Fig. 6A by reverse genetics using the pHW18* series of WSN reverse genetics plasmids (52),
but substituting the appropriate mutant plasmid listed in File S6 for the wild-type plasmid for
that gene. To generate the viruses from these plasmids, we transfected an equimolar mix of
all eight plasmids into co-cultures of 293T and MDCK-SIAT1 cells seeded at a ratio of 8:1. At
24 hours post-transfection, we changed media from D10 to influenza growth media. At 50
hours post-transfection (for the replicate 1 viruses in Fig. S12A) or 72 hours (for the replicate 2
viruses in Fig. S12), we harvested the virus-containing supernatant, clarified this supernatant
by centrifugation at 300×g for 4 min, and stored aliquots of the clarified viral supernatant at
-80◦C. We then thawed aliquots and titered by TCID50 on MDCK-SIAT1 cells. For the infections
in Fig. S12A, we wanted to use equivalent particle counts, so we normalized all viruses to an
equivalent hemagglutination titer on turkey red blood cells (86). Briefly, a solution of 10% v/v
red blood cells (LAMPIRE Biological Laboratories, Fisher Scientific catalogue number 50412942)
was washed in PBS and diluted to a final concentration of 0.5% v/v. Two-fold serial dilutions
of virus were added to an equal volume of diluted red blood cells, and titer was measured
as the highest dilution of viral stock at which complete hemagglutination of red blood cells
was observed. We then performed infections of the A549 reporter cell line at equivalent
hemagglutination titer and analyzed the data as described in Fig. S12A.
To generate the NS1stop mutant virus and the wild-type and PB1del385to2163 mutant
viruses in Fig. S12B, we used slightly different procedures. The wild-type virus was generated
by reverse genetics as described for the point-mutant viruses above, harvested at 48 hours
post-transfection, and then passaged on MDCK-SIAT1 cells for 36 hours at an MOI of 0.05—
conditions that we previously validated to lead to relatively little accumulation of defective
particles (12). The NS1stop virus was similarly generated, but was passaged for 48 rather than
36 hours, since it had slower growth kinetics and so needed a longer period of time to reach
high titers. The viruses with deletions in the PB1 segment could not be generated in normal
293T and MDCK-SIAT1 cells, since they required the exogenous expression of the PB1 protein.
Therefore, these viruses were generated in previously described 293T and MDCK-SIAT1 cells
that had been engineered to constitutively express PB1 (87). These viruses were harvested
from transfections at 72 hours, and passaged twice in the MDCK-SIAT1 cells constitutively
expressing PB1 at a MOI of 0.001 for 72 hours and 0.01 for 48 hours. This passaging was
necessary as viral titers from transfections were too low to generate sufficient virus from a
single passage. The wild-type and NS1stop viruses were titered by TCID50 on MDCK-SIAT1 cells,
and the PB1 deletion viruses were titered on the MDCK-SIAT1 cells constitutively expressing
PB1. The infections in Fig. S12B were performed at equivalent TCID50s as described in the
legend to that figure. That these equivalent TCID50s were also roughly equivalent in terms of
particles capable of undergoing primary transcription is shown in Fig. S13.
Computational analysis of single-cell transcriptomic and viral sequence data. A com-
putational pipeline that performs all steps in the data analysis is available at https://github.
com/jbloomlab/IFNsorted_flu_single_cell. This pipeline is orchestrated by Snakemake (88), and
begins with the raw sequencing data and ends by generating the figures shown in this paper.
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The sequencing data and annotated cell-gene matrix are available on the GEO repository under
accession GSE120839 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120839).
Briefly, the raw deep sequencing data from the Illumina 3’-end sequencing were processed
using the 10X Genomics software package cellranger (version 2.2.0). We built a multi-species
alignment reference consisting of a concatenation of the human and influenza virus transcrip-
tomes (the first “species”) and the canine transcriptome (the second “species”). The human
transcriptome was generated by filtering genome assembly GRCh38 for protein-coding genes
defined in GTF file GRCh38.87. The influenza virus transcriptome consisted of the mRNAs for
the wild-type A/WSN/1933 virus strain in File S2 (the cellranger alignment is sufficiently permis-
sive that it aligns sequences from both the wild-type and synonymously barcoded viral variants
to this transcriptome). The canine transcriptome was generated by filtering genome assembly
CanFam3.1 for protein-coding genes defined in GTF file CanFam3.1.87. The cellranger software
was used to align the Illumina 3’-end sequencing reads to this multi-species transcriptome, call
human+influenza and canine cells (Fig. 3A), and generate a matrix giving the expression of each
gene in each single cell. We used a custom Python script to determine the number of influenza
virus reads that could be assigned to the wild-type or synonymously barcoded virus, and added
this information to the annotated the cell-gene matrix.
The PacBio sequences of the full-length viral genes were analyzed as follows. First, we
used version 3.1.0 of PacBio’s ccs program (https://github.com/PacificBiosciences/unanimity) to
build circular consensus sequences (CCSs) from the subreads files, requiring at least 3 passes
and a minimum accuracy of 0.999. We further processed these CCSs using custom Python
code and the minimap2 (89) long-read aligner (version 2.11-r797). The Python code has been
implemented in the API of dms_tools2 (https://jbloomlab.github.io/dms_tools2/ (90)) package
(version 2.3.0). A Jupyter notebook that performs these analyses is at https://github.com/
jbloomlab/IFNsorted_flu_single_cell/blob/master/pacbio_analysis.ipynb, and is also provided
in HTML form as File S7. We refer the reader to this notebook for a detailed description and
extensive plots showing the results at each step. Here is a brief summary: we filtered for
CCSs that had the expected 5’ termini (from the influenza-specific primers) and 3’ termini
(corresponding to the 10X adaptor), and for which we could identify the cell barcode, UMI, and
polyA tail. We aligned the cDNAs flanked by these termini to the influenza transcriptome, and
performed a variety of quality control steps. At this point, we examined whether cDNAs had
the synonymous viral barcodes at both ends or neither end as expected in the absence of
strand exchange (Fig. S10), and reassuringly found that strand exchange was rare (Fig. S9). The
small number of CCSs with identifiable strand exchange were filtered from further analysis. We
then further filtered for CCSs that contained valid cell barcodes as identified by the cellranger
pipeline, and kept just one CCS per UMI (preferentially retaining high-quality CCSs that aligned
to full-length cDNAs). We then removed from the CCSs the barcoding synonymous mutations
that we had engineered into one of the two viral variants. Finally, we used the CCSs to
call the sequence of the viral gene in each cell, calling mutations separately for each viral
barcode variant. We called mutations (insertions, deletions, and substitutions) in the viral gene
sequences as follows:
1. Mutations with accuracies less than 0.999 (which constitute <0.5% of all mutations)
were ignored.
2. If all CCSs for a particular viral-barcode variant of a gene in a cell were wild-type, it was
called as wild type.
3. If any CCSs for a particular viral-barcode variant of gene in a cell had a mutation, then
require at least two CCSs to call the sequence.
4. If at least two and >30% of the CCSs had a specific mutation, then call that mutation as
present and note its frequency among the CCSs. The exception was single-nucleotide
indels in homopolymers, for which we required three CCSs to call a mutation (the reason
is that the main mode of PacBio sequencing errors is short indels in homopolymers).
The plots in File S7 indicate that these are reasonable mutation-calling criteria. We could call
the sequences of all expressed viral genes in about half of the infected cells (Fig. S11). The
mutations called using this pipeline are shown in Fig. 4, and File S4 gives the number of CCSs




Finally, we process the annotated cell-gene matrix in R to generate the plots shown in
this paper. This analysis utilized a variety of R and Bioconductor (91) packages, including
Monocle (92, 93) and ggplot2. A Jupyter notebook that performs these analyses is at https:
//github.com/jbloomlab/IFNsorted_flu_single_cell/blob/master/monocle_analysis.ipynb, and
is also provided in HTML form as File S8. We refer the reader to this notebook for a detailed
description and a variety of additional plots not included in the paper. Briefly, we first filtered
cells that were extreme outliers in the amount of mRNA as shown in Fig. 3B. We used the
uninfected canine cells to estimate the percentage of total mRNA in a cell that would come
from influenza purely due to background (e.g., from cell lysis) in the absence of infection, and
called as infected the human cells for which significantly more than this amount of mRNA
was derived from influenza under a Poisson model (Fig. 3C). We next used a Poisson model
parameterized by the amount of expected background mRNA for each influenza gene to call
the presence or absence of each influenza gene in each infected cell (Fig. 3D and Fig. S4). To
identify cells that were co-infected with both viral barcodes (Fig. 3F), we used a binomial test
to identify cells for which we could reject the null hypothesis that at least 95% of viral mRNA
was derived from the more common viral barcode. We called IFN+ and ISG+ cells using the
heuristic thresholds shown in Fig. 3G and Fig. S6, respectively. We counted IFN mRNAs as any
IFN-α , IFN-β , or IFN-λ transcripts. We counted ISG mRNAs as any of CCL5, IFIT1, ISG15, or Mx1.
The plot in Fig. 4 summarizes all of the genotypic information, and was created in substantial
part using gggenes (https://github.com/wilkox/gggenes). The raw data are in File S4 and File S5.
Structural analysis of PB1 mutants. To locate the PB1 mutations in the influenza A virus
RNA polymerase structure relative to the template and active site in Fig. 8A, we superposed the
bat influenza A virus RNA polymerase structure (PDB 4WSB) (74), which shows the 3’ terminus
of the template on the surface of the RNA polymerase, with the influenza B virus transcription
initiation complex (PDB 5MSG) (75), which shows the 3’ terminus of the template in the template
entry channel that leads towards the active site. The structural alignment was performed in
Pymol 1.8.7 using motifs A and C.
Experimental analysis of PB1 mutants. For the experimental analysis of the PB1 mu-
tants in Fig. 8, we used plasmids pcDNA-PB1, pcDNA-PA, pcDNA-PB2, and pcDNA-NP, which
encode the WSN proteins that compose the polymerase complex (94); pPolI-NA, which encodes
the viral RNA for the WSN NA (94); and pcDNA-PB1a, which encodes an inactive version of
the WSN PB1 polymerase protein (95). To construct plasmids expressing mutant PB1 proteins
D27N and T677A, the plasmid pcDNA-PB1 was subjected to site-directed mutagenesis. PB1
expression was analysed by western blot using antibody GTX125923 (GeneTex).
To analyze the activity of the PB1 mutants in cell culture, the plasmids expressing the
WSN PA, PB2, NP and PB1 proteins were transfected into 293T cells together with the plasmid
expressing the wildtype NA vRNA or a 246-nt long segment NP-based template (35). Twenty-
four hours post transfection, the RNA was extracted using Trizol (Invitrogen), and the steady
state RNA levels assessed using reverse transcription with 32P-labelled oligonucleotides against
the viral RNA species and ribosomal 5S RNA as described previously (35, 96). 32P-derived
signals were imaged using phosphorimaging on a Typhoon scanner and analysed using Prism
(GraphPad). In all experiments, the apparent RNA levels were background corrected using the
PB1a mutant and normalized to the 5S rRNA loading control.
To measure the induction of the IFN-beta promoter during these RNP reconstitution
assays, they were carried out in the presence of a plasmid expressing Renilla luciferase from
a CMV promoter and a plasmid expressing Firefly luciferase from the IFN-beta promoter (35).
Twenty-four hours post transfection, cells were harvested, lysed and analysed using a DualGlo
luciferase kit (Promega) according to the manufacturer’s instructions. Samples were analysed
using a GloMax (Promega).
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Influenza stock 1 Influenza stock 2
Influenza PB1 deletion Influenza NS1 mutation
FIG S1 Validation of reporter cell lines (Fig. 1A) to identify IFN+ cells. (A) To validate
the IFN reporter cell lines, they were infected at high MOI with the Cantell strain of
Sendai virus, which strongly activates IFN expression. The name of each of reporter cell
line is indicated at the top of each row of plots. At 13 hours post-infection, activation
of the IFN reporter was then monitored by flow cytometry using the marker indicated
at the bottom of each plot (either a fluorescent protein or antibody staining for the
cell-surface LNGFR∆C using a PE-conjugated anti-LNGFR antibody from Miltenyi Biotec).
Sendai infection efficiently activated the IFN reporter in all cases, with the strongest
signal from the IFN-λ reporter driving ZsGreen. (B) The type I and type III IFN reporters
are highly correlated in their activation. An A549 cell line was generated by transduction
with both the IFN-β and IFN-λ reporters driving expression of mCherry and ZsGreen,
respectively. The cells were then infected with two different stocks of “wild-type”WSN
influenza, or stocks with a deletion in PB1 or stop codons in NS1 (described later in the
paper). After 13 hours, cells were analyzed by flow cytometry. Cells positive for either
fluorescent reporter were further analyzed. As shown in the FACS plots, expression of

































































































































FIG S2 Flow cytometry data for Fig. 1B. The A549 cells with the IFNL1 reporter driving
LNGFR∆C-ZsGreen were not infected, infected with saturating amounts of the Cantell
strain of Sendai virus, or infected the same stock of influenza virus used in the single-
cell experiment at a target MOI of 0.3. After 13 hours, the cells were stained for
expression of HA protein and analyzed by FACS for HA and expression of the ZsGreen
driven by the IFNL1 reporter. Each condition was done in triplicate. The contour plots
show the density of all cells, and all IFN+ cells are also indicated by orange dots. Cells
were classified as HA+ or IFN+ based on gates set to put 0.05% of the uninfected
cells in these populations. For the influenza-infected cells, the percentage IFN+ was
calculated only among the HA+ cells (since these are the ones that are infected). For
the uninfected and Sendai-virus infected, the percentage IFN+ was calculated among
all cells, since these cells do not express HA.
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FIG S3 Example MACS enrichments of IFN+ influenza-infected cells. A549 cells with
the IFNB1 LNGFR∆C-mNeonGreen reporter were infected with wild-type WSN influenza
(two different viral stocks) at a target MOI of 0.1 TCID50 per cell. After infection had
proceeded for 12 hours, the cells were twice magnetically sorted for LNGFR∆C expres-
sion over magnetic columns as detailed in the methods for the single-cell sequencing
experiment. (A) After sorting, the populations were analyzed by flow cytometry for
IFN expression using the mNeonGreen fluorescent protein. The plots show the dis-
tribution of fluorescence in the original population, the flow-through from the first
column, and the MACS-sorted positive population after two columns. As indicated by
the percentages shown for the original and MACS-sorted population, this process led
to substantial enrichment in IFN+ cells. We expect that the IFN sorting for the actual
single-cell sequencing led to similar enrichment, although we could not directly quantify
this as the sorted cells in that case were immediately used for the sequencing and so
could not be analyzed by flow cytometry. (B) Analysis of expression of IFNB1 (relative
to the housekeeping gene L32) by qPCR in the positive (IFN enriched) and negative
(IFN depleted) populations from panel (A). The qPCR validates a roughly 50- to 100-fold
enrichment in total IFNB1 expression. The qPCR was performed in quadruplicate






























FIG S4 The fraction of infected cells that are called as expressing each viral gene.
The gray dashed line is at one (the fraction that would be observed if all viral genes
are expressed in all infected cells). Each viral gene is detected in ∼80-90% of the
infected cells. The exception is NP, which is detected in virtually all infected cells. The
much higher frequency of detecting NP could reflect a biological phenomenon, but
we suspect it is more likely that cells lacking NP tend to have much lower viral gene
expression overall and so are not reliably called as being infected in our experiments



























9 of 41 IFN+
31 of 109 IFN+
FIG S5 There is no association between viral co-infection and expression of IFN in our
experiments using low MOI infections with a relatively “pure” viral stock. Histograms
show the fraction of all cellular mRNA derived from IFN among cells expressing viral
mRNA from just a single viral barcode variant, or cells expressing viral mRNA from both
the wildtype and synonymously barcoded viral variants. The dual-barcode cells repre-
sent known co-infections, whereas the single-barcode cells represent a mix of singly
infected cells and co-infections with the same viral barcode. There is no significant
difference in the frequency of IFN induction among the two classes of cells (P = 0.53,
Fisher’s exact test).
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R = 0.39 , p < 2.2e−16
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FIG S6 Expression of ISGs in single infected and uninfected cells. For each cell,
we quantified ISG expression as the total fraction of cellular mRNAs derived from
four prototypical ISGs (IFIT1, ISG15, CCL5, and Mx1). (A) The histograms show the
distribution of ISG expression taken across infected (top) and uninfected (bottom)
cells. We heuristically classify as ISG+ cells with > 10−3 of their cellular mRNA from
ISGs, and color these cells red. Comparison to Fig. 3G shows that substantially more
cells are ISG+ than IFN+, both among infected and uninfected cells. This is probably
because paracrine signaling can induce ISG expression in cells that are not themselves
expressing IFN. (B) Correlation between the fraction of cellular mRNA derived from
IFN and ISGs. Each point represents one cell, and the Pearson correlation coefficient
is shown. IFN and ISG expression are more correlated for infected than uninfected
cells, probably because in the latter the ISG expression is more often due to paracrine
signaling that does not induce expression of IFN itself. Among both the infected and
uninfected populations, there are many cells with high expression of ISGs and little
expression of IFN, but no cells that express high levels of IFN without also substantially
expressing ISGs.
R = 0.83 , p < 2.2e−16 R = 0.83 , p < 2.2e−16
infected not infected


















FIG S7 The correlation between the fraction of cellular mRNA derived from type I and
type III IFN in the A549 cells in our single-cell transcriptomics. Each point represents
one cell. The plots are faceted by whether the cells are called as infected, and the
Pearson correlation coefficient is shown. Because type I and type III IFN expression are
highly correlated, for the remainder of the paper we group them together and refer to









































































































FIG S8 Unsupervised t-SNE clustering shows that cell-to-cell variation in expression
of influenza, IFN, and ISG transcripts substantially contributes to the structure of the
data. To generate an unbiased representation of the factors that distinguished the
transcriptomes of the cells in our experiments, we used unsupervised t-SNE clustering
as implemented in Monocle to generate a two-dimensional representation of the data.
In the t-SNE plot, each point is a different cell, and cells with similar transcriptomes
are closer together. Each panel shows the same t-SNE plot, but the cells are colored
differently in each panel based on the amount of viral, IFN, or ISG mRNA, shown on a
log (top) or linear (bottom) scale. As is clear from this plot, expression of influenza, IFN,
and ISG genes contributes substantially to the structure of the data, since cells with
high expression of these genes clearly group together.
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estimated frequency of PCR chimeras: 0.057
FIG S9 The number of PacBio CCSs that passed quality-control steps and aligned to
an influenza virus gene. These sequences were obtained using several PacBio runs,
most of which were intentionally loaded with different amounts of the various viral
genes to increase coverage on genes that were needed in order to obtain the full
sequences of virions infecting cells (see File S7). Because of this unequal loading and
the inherently different PCR amplification efficiencies of different viral genes, unlike
the transcriptomic data in Fig. 3, the numbers of CCSs for different genes should not
be taken as an indicator of their abundance in the infected cells. Especially for the
polymerase genes (PB2, PB1, and PA), many CCSs corresponded to genes with internal
deletions, since these shorter forms of the genes were preferentially amplified during
PCR. Therefore, the plot is faceted by the number of CCSs for any length of the gene,
and for full-length genes. Note that the disproportionate sequencing of the shorter
internally deleted genes does not greatly affect the genotype calling in Fig. 4 since UMIs
were used to collapse sequences derived from the same cDNA, and cell barcodes were
used to collapse sequences from the same cell. The bars in the plot are colored by
whether the sequence is derived from the wild-type viral variant, the synonymously
barcoded viral variant, or represents a mixed-barcode molecule (see panel B). From the
frequencies of these different forms, we estimate that 5.7% of molecules are chimeric
due to PCR strand exchange. About half of these PCR chimeras could be identified
by the presence of mixed viral barcodes and removed from subsequent analyses,
leaving ∼3% un-identified chimeras. For some molecules (mostly polymerase genes
with internal deletions) one of the barcode sites was deleted from the molecule and so
the barcode identity could only be partially called. A negligible number of molecules























Cells are infected with a 
mix of wildtype virus and 
virus with synonymous 
barcodes at both ends of 
every gene. 
We expect PacBio 
sequences to be 
wildtype or barcoded at 
both ends. 
Mixed barcode 
sequences indicate PCR 
strand exchange. 
FIG S10 Strategy for detecting strand exchange during sequencing of full-length viral
genes. The library preparation for PacBio sequencing of the cDNA for the full-length
viral genes required many cycles of PCR. A major concern is that strand exchange
during this PCR could scramble mutations and 10X cell barcodes / UMIs from different
molecules. We detect PCR strand exchange by leveraging the fact that our cells were
infected with a mix of wild-type virus and virus carrying synonymous barcodes near
both termini of each gene. If there is no strand exchange, all molecules should either
be wild-type or have the synonymous barcoding mutations at both termini. Strand
exchange will create some molecules that have wild-type nucleotides at one termini
and synonymous barcoding mutations at the other termini. Fig. S9 shows the frequen-
cies with which these different types of molecules were observed during the PacBio
sequencing. Note that since the rate of homologous recombination in influenza virus
in negligible, such mixed-barcode molecules are not expected to be generated naturally
during co-infection.
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FIG S11 Number of cells for which we could determine the full sequences of all genes
expressed by the infecting virion(s). (A) We could call the complete genotypes of the
infecting virion(s) for the majority of cells infected with just a single viral barcode
variant, but only a minority of cells co-infected with both viral barcodes. (B) The cells
for which we could call complete viral genotypes tended to have higher expression of
viral mRNA than cells for which we could not call complete genotypes. Both facts make
sense. Cells with more viral mRNA are more likely to have their viral cDNA captured in
the PacBio sequencing, which is only captures a small fraction of the total transcripts
identified by the 3’-end sequencing transcriptomic sequencing. The lower calling rate
for dual-barcode co-infections is probably because these co-infections have more
viral genes that must be sequenced (potentially a copy of each viral gene from each
viral variant), increasing the chances that one of these genes is missed by the PacBio
sequencing. An important implication of this plot is that the cells for which we call
complete viral genotypes are not a random subsampling of all infected cells in the
experiment, but are rather enriched for cells that have high levels of viral mRNA and do
not have dual-barcode viral infections. Note also that this plot is limited to the cells that












































































































































































FIG S12 Flow cytometry data for Fig. 6. (A) Data for Fig. 6A. A549 cells with the IFNL1
reporter driving LNGFR∆C-ZsGreen were infected with stocks of the indicated mutant.
After 13 hours, cells were stained for HA protein and analyzed by FACS. Contour plots
show density of all cells, and IFN+ cells are also indicated by orange dots. Cells were
classified as HA+ or IFN+ based on gates set to put 0.05% of uninfected cells in these
populations. For infected cells, the percentage IFN+ was calculated among the HA+
cells (since these are the ones that are infected). For uninfected cells, the percentage
IFN+ was calculated among all cells, since uninfected cells do not express HA. For each
viral mutant, two independent stocks were assayed in duplicate (i.e., #1a and #1b are
one viral stock, and #2a and #2b are the other). The infections with replicate #1 of
the wild-type virus were performed at an MOI of 0.1 as determined by TCID50, and
all other viruses were infected at an equivalent particle number as determined by HI
assay. (B) Data for Fig. 6B. The virus with the deletion in PB1 cannot be normalized by
HA expression since it expresses less HA due to the lack of secondary transcription.
Therefore, all cells were infected at an equivalent MOI of 0.3 as determined by TCID50
on MDCK-SIAT1 cells for wild type and NS1stop, and on MDCK-SIAT1 cells expressing
PB1 for PB1del385to2163. Fig. S13 shows that at these equivalent TCID50s, all variants
had similar amounts of transcriptionally active virus in the absence of secondary
transcription. The percent IFN+ was calculated for all cells (HA+ and HA-) since that is a
more fair comparison for PB1del385to2163.
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FIG S13 Validation that the infections in Fig. 6B and Fig. S12B were performed at
similar doses of virions capable of initiating primary transcription. In this experiment,
A549 cells were infected at MOI of 0.4 (based on TCID50 as described in Fig. S12B), and
then after 8 hours mRNA was harvested for qPCR on oligo-dT primed reverse transcrip-
tion products. The y-axis shows the ratio of viral HA mRNA to the housekeeping gene
L32. These infections were performed in the presence of absence of 50 µg/ml cyclo-
heximide, which blocks protein synthesis and hence secondary transcription by newly
synthesized viral proteins. In the absence of cycloheximide, the viruses with deletions
in PB1 produced less viral mRNA presumably because they could not produce PB1
protein for secondary transcription. But in the presence of cycloheximide, all viruses
produced similar amounts of viral mRNA, indicating that the dose of particles active for




























































FIG S14 A more detailed version of the data summarized in Fig. 7. For each virus and
replicate, we binned the infected cells in Fig. S12 into HA expression quartiles based on
the flow cytometry measurements. We then calculated the percent of cells that were
IFN+ in each quartile. The plots show the mean HA expression of the quartile versus
the precent of cells that are IFN+. The results clearly show that for the NS1stop and to
a lesser extent the NS1-A122V variants, more viral protein (higher HA signal) correlates
with IFN induction. Fig. 7 summarizes these same data by simply showing the ratio of
percent IFN+ between the highest and lowest quartile.
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FILE S1 Sequences of the IFN reporters in Fig. 1A are at https://github.com/
jbloomlab/IFNsorted_flu_single_cell/tree/master/paper/figures/IFN_stochastic/IFN_
reporter/plasmids. This file is also available on Data Dryad Digital Repository at
https://doi.org/10.5061/dryad.nh053c6.
FILE S2 Genbank files giving sequences of the wild-type and synonymously bar-
coded viruses are at https://github.com/jbloomlab/IFNsorted_flu_single_cell/blob/
master/data/flu_sequences/flu-wsn.gb and https://github.com/jbloomlab/IFNsorted_
flu_single_cell/blob/master/data/flu_sequences/flu-wsn-double-syn.gb. This file is also
available on Data Dryad Digital Repository at https://doi.org/10.5061/dryad.nh053c6.
FILE S3 A text file giving the primers used to amplify the influenza cDNAs for PacBio
sequencing is at https://github.com/jbloomlab/IFNsorted_flu_single_cell/tree/master/
paper/figures/WorkflowSchematic/PacBio_primer_list.txt. This file is also available on
Data Dryad Digital Repository at https://doi.org/10.5061/dryad.nh053c6.
FILE S4 A CSV file giving the genotypes in Fig. 4 is at https://github.com/
jbloomlab/IFNsorted_flu_single_cell/blob/master/paper/figures/single_cell_figures/
genotypes.csv. This file is also available on Data Dryad Digital Repository at
https://doi.org/10.5061/dryad.nh053c6.
FILE S5 A CSV file giving the viral mutations and related information in Fig. 5 is
at https://github.com/jbloomlab/IFNsorted_flu_single_cell/blob/master/paper/figures/
single_cell_figures/mutations.csv. This file is also available on Data Dryad Digital Repos-
itory at https://doi.org/10.5061/dryad.nh053c6.
FILE S6 Genbank plasmid maps for the mutant genes cloned into the pHW* bi-
directional reverse genetics plasmid are at https://github.com/jbloomlab/IFNsorted_flu_
single_cell/tree/master/paper/figures/FluVariantPlasmidMaps. This file is also available
on Data Dryad Digital Repository at https://doi.org/10.5061/dryad.nh053c6.
FILE S7 The Jupyter notebook that analyzes the PacBio data is at https://github.com/
jbloomlab/IFNsorted_flu_single_cell/blob/master/pacbio_analysis.ipynb. This file is also
available on Data Dryad Digital Repository at https://doi.org/10.5061/dryad.nh053c6.
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FILE S8 The Jupyter notebook that analyzes the annotated cell-gene matrix
is at https://github.com/jbloomlab/IFNsorted_flu_single_cell/blob/master/monocle_
analysis.ipynb. This file is also available on Data Dryad Digital Repository at https:
//doi.org/10.5061/dryad.nh053c6.
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